Ensysce Biosciences (ENSC) vs GT Biopharma (GTBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GT Biopharma is the larger company by market cap ($12.1 million vs $10.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENSC | GTBP |
|---|---|---|
| Share price | $0.527 | $6.68 |
| Market cap | $10.25M | $12.05M |
| 1-day change | +15.07% | +12.27% |
| YTD return | — | +750.96% |
| 1-year return | — | +789.48% |
| 5-year return | — | -96.32% |
| EPS (TTM) | $-2.47 | $-161.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.75 | $28.75 |
| 52-week low | $0.23 | $4.91 |
| Distance from 52-week high | -80.84% | -76.77% |
| Analyst consensus | none | none |
| Avg. price target upside | +1465.46% | +1022.75% |
| Average volume | 14.43M | 55.52K |
| Shares outstanding | 19.46M | 1.80M |
| Employees | 8 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ensysce Biosciences
ENSC stock →Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
ENSC vs GTBP FAQ
Which is bigger, Ensysce Biosciences or GT Biopharma?
GT Biopharma (GTBP) is larger, with a market capitalization of $12.05M compared with $10.25M for Ensysce Biosciences (ENSC).
Are Ensysce Biosciences and GT Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.